Predicting the risk of dangerous heart rhythms or heart failure in inherited heart disease
Studies blood samples and heart data to estimate risk in people with inherited heart disease.
Key facts
- Who runs it
- Nantes University Hospital
- Where
- Saint-Pierre, RéunionSee the siteAlso in 2 other countries, 14 sites
- Trial code
- Registry title
- Stratification of Arrhythmic Risk and/or Heart Failure Risk in Patients With Hereditary Heart Disease
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 3 Feb 2026
- Expected to end
- 12 Dec 2036
- Type of study
- Observational
- Treatments tested
- Blood sample
- Record updated
- 27 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with a hereditary heart disease, their relatives, and patients sent to the reference centre for suspected inherited rhythm disorders or heart muscle disease.
- Age
- 1 Year to 100 Years
- Sex
- All sexes can join.
- Disease stage
- Hereditary heart disease (inherited rhythm disorders or cardiomyopathies).
Main reasons for not taking part
- Taking part in a treatment trial that may affect the results of this research
- Being under guardianship or curatorship
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- hereditary heart disease II. All relatives of patients III. Patients referred to the reference centre for suspected hereditary rhythm disorders or cardiomyopathies IV. Written consent V. social security scheme
Who cannot take part
- Patients participating in a therapeutic trial that may interfere with the research results II. Patients under guardianship or curatorship
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 100 years old?
Where in Réunion
Also in 2 other countries, 14 sites
- CHU de La RéunionSaint-Pierre, RéunionContact: WIART FrançoisNot yet recruiting
About the trial
What the trial wants to find out
Sudden cardiac death (SCD) is one of the leading causes of death in developed countries. These deaths (more than 5,000 per year in France) are due to hereditary arrhythmias or cardiomyopathies. Early diagnosis of SCD is often achieved through family screening, but the main challenge is to stratify the risk of SCD in these patients. Indeed, prevention of SCD relies mainly on the implantation of an automatic defibrillator. The challenge is to identify patients who will develop SCD and avoid implanting an implantable cardioverter defibrillator (ICD) in patients who will never develop arrhythmias but who will face complications related to the ICD (inappropriate shocks, infection, lead failure), leading to a reduced quality of life and significant costs for the healthcare system. However, there is a lack of relevant clinical and biological markers for risk stratification, which rules out any possibility of preventive screening. Most of the clinical and ECG (electrocardiogram) parameters identifying an increased risk of SCD have not been reproduced in replication studies.
Read full original descriptionShow less
In this project, the investigator will develop a data processing and analysis pipeline using artificial intelligence methods to assess the individual risk of serious arrhythmic events or heart failure in patients with hereditary arrhythmic diseases or cardiomyopathies through the automated processing of multimodal data (clinical data, electrocardiogram (ECG), imaging (echocardiography, MRI magnetic resonance imaging), genetic data, biomarkers).
Treatments tested
- Blood sample
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Stratification of Arrhythmic Risk and/or Heart Failure Risk in Patients With Hereditary Heart Disease
- Plain-language title
- Predicting the risk of dangerous heart rhythms or heart failure in inherited heart diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07257289, who can take part
- Record updated
- 27 October 2026